Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma

Hematology

Volumn 20, Issue 4, 2015, Pages 196-202

  Arai, Yasuyuki ^a   Yamashita, Kouhei ^a   Mizugishi, Kiyomi ^a   Nishikori, Momoko ^a   Hishizawa, Masakatsu ^a   Kondo, Tadakazu ^a   Kitano, Toshiyuki ^a   Kawabata, Hiroshi ^a   Kadowaki, Norimitsu ^a   Takaori Kondo, Akifumi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Adverse effect; CD20; Infection; Neutrophil; Non Hodgkin lymphoma

Indexed keywords

ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SENESCENCE; UNIVARIATE ANALYSIS; VERY ELDERLY; CHEMICALLY INDUCED; LYMPHOMA, B-CELL; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RITUXIMAB; YOUNG ADULT;

EID: 84928530543     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000188     Document Type: Article

References (29)

1. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(1. Suppl 2):3–8
2. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237–50
3. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) 2012;51(5):833–40
4. Gregersen JW, Jayne DR. B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol. 2012;8(9):505–14
5. Fehr T, Stussi G. ABO-incompatible kidney transplantation. Curr Opin Organ Transplant. 2012;17(4):376–85
6. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy – rare but there! Leuk Lymphoma 2009;50(7):1083–95
7. Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol. 2011;4(6):619–25
8. Tesfa D, Ajeganova S, Hagglund H, Sander B, Fadeel B, Hafstrom I, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209–14
9. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21(24):4489–95
10. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103(10): 3684–8
11. Okamoto M, Maruyama F, Tsuzuki M, Nomura T, Miyazaki H, Wakita M, et al. Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin’s lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin. Rinsho Ketsueki. 1994;35(7):635–41
12. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol. 2012;19(1):32–8
13. Lemieux B, Tartas S, Traulle C, Espinouse D, Thieblemont C, Bouafia F, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non- Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33(9): 921–3
14. Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, et al. A high incidence of late-onset neutropenia following rituximabcontaining chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol. 2007;18(2):364–9
15. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006;47(6):1013–7
16. Cairoli R, Grillo G, Tedeschi A, D’Avanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica. 2004;89(3):361–3
17. Hirayama Y, Kohda K, Konuma Y, Hirata Y, Kuroda H, Fujimi Y, et al. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. Intern Med. 2009; 48(1):57–60
18. Keane C, Nourse JP, Crooks P, Nguyen-Van D, Mutsando H, Mollee P, et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Intern Med J. 2012;42(10):1113–9
19. Li SC, Chen YC, Evens AM, Lee CC, Liao HF, Yu CC, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol. 2010;85(10):810–2
20. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158. V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28(2):279–84
21. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003;19(4):583–93
22. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005;106(3):795–802
23. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004;20(6):707–18
24. Geiger H, Rudolph KL. Aging in the lympho-hematopoietic stem cell compartment. Trends Immunol. 2009;30(7):360–5
25. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010;10(6):425–34
26. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol. 2009;84(7):428–34
27. Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol. 2008;25(4):374–9
28. Hincks I, Woodcock BE, Thachil J. Is rituximab-induced lateonset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol. 2011;153(3):411–3
29. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89(5):308–18.